Description
GLP1-S is a synthetic analog of GLP-1, molecular formula C187H291N45O59, molecular weight 4,113.64 g/mol, CAS 910463-68-2, first described in the scientific literature in 2007, classified as a GLP-1 receptor agonist.
The structural modifications that distinguish GLP1-S from native GLP-1 are well characterized in the incretin research literature: substitution of alanine at position 8 with alpha-aminoisobutyric acid (Aib), which resists DPP-4 enzymatic breakdown, and a C-18 fatty diacid chain attached via a linker at position 26, which enables albumin binding for an extended half-life. These are the same category of modifications used in semaglutide, giving GLP1-S a strong mechanistic grounding in one of the most extensively studied drug classes in modern pharmacology, GLP-1 receptor agonists, which include approved drugs like Ozempic, Wegovy, and Victoza. Native GLP-1 itself breaks down within minutes in circulation, which is precisely the limitation these structural modifications are designed to address.
GLP1-S appears as a white lyophilized powder that is soluble in water. This product is strictly for research purposes only.
PubChem Reference: View compound profile on NIH PubChem
Key Characteristics
MOLECULAR PROFILE
Formula: C₁₈₇H₂₉₁N₄₅O₅₉
Weight: 4113.641 g/mol
CAS: 910463-68-2
Structure: Modified GLP-1 analog
PHYSICAL PROPERTIES
Form: White lyophilized powder
Solubility: Water-soluble
Half-life: Extended duration
Storage: Keep refrigerated 36‑46 °F (2‑8 °C)
GLP1-S in Published Research
GLP-1 receptor agonism is one of the most clinically validated peptide mechanisms in existence, backed by large-scale outcome trials for glycemic control and weight loss across multiple approved drugs. GLP1-S’s specific modifications (Aib8 substitution, C18 diacid at position 26) match published semaglutide research closely enough that researchers studying it can draw on that broader GLP-1 agonist literature for mechanistic context, while treating GLP1-S itself as a distinct research compound rather than assuming identical pharmacokinetics.
Frequently Asked Questions :
What is GLP1-S studied for?
GLP-1 receptor agonism, relevant to glycemic control and appetite-regulation research, among the most clinically validated peptide mechanisms available.
How is it related to semaglutide?
It shares the same category of structural modifications (Aib8 substitution, C18 fatty diacid linker) used in semaglutide, though it is a distinct research compound.
Dr. Sophia L. Bennett –
Solid GLP1-S works exactly as expected in our insulin secretion assays. The lyophilized powder arrived intact with prompt shipping to Canada. Minor note: a longer expiration date would be appreciated, but quality is excellent
Prof. James T. Harrington –
Very reliable peptide for incretin research. Reconstitutes easily and remains stable in solution for up to 48 hours. Would give 5 stars if the vial included a desiccant packet, but the product itself is top-notch
Dr. Fatima Z. Al-Mansoori –
performance across multiple batches. GLP1-S from Peptides Vital outperformed samples from two other vendors in our cAMP activation assays. Highly recommend for any GLP-1 receptor studies.
Dr. Elena R. Hofmann –
Excellent quality GLP1-S. Our GLP-1 receptor activation assays showed potent and reproducible results. CAS 910463-68-2 confirmed via LC-MS. The 99% purity claim is accurate no visible impurities
Prof. Lukas P. Novak –
Consistent 99% purity as advertised. Our HPLC analysis showed a single sharp peak with no degradation byproducts. CAS 910463-68-2 verified. Will definitely reorder for our ongoing metabolic research